# OnCo record atrt (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/atrt/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "atrt" ;
  schema:name "Atypical teratoid/rhabdoid tumour (ATRT)"@en ;
  schema:alternateName "AT/RT"@en, "Rhabdoid tumour of the CNS"@en, "Rhabdoid tumour predisposition syndrome"@en ;
  schema:description "ATRT is an aggressive brain tumour of babies and toddlers caused by loss of a single gene, SMARCB1, part of the machinery that opens and closes DNA. Intensive chemotherapy with stem-cell rescue, and radiotherapy where age allows, now cure a meaningful share of children who once had little chance, and drugs aimed at the epigenetic consequence of SMARCB1 loss (EZH2 inhibitors) are in trials."@en ;
  schema:url <https://onco.cc/cancers/atrt/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Atypical_teratoid_rhabdoid_tumor> ;
  schema:citation <https://www.cancer.gov/types/brain/hp/child-cns-atrt-treatment-pdq>, <https://doi.org/10.1200/JCO.19.01776>, <https://doi.org/10.1093/neuonc/noz244> ;
  onco:tag "nci-coverage", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/epithelioid-sarcoma/>, <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/wilms-tumor/>, <https://onco.cc/cancers/ependymoma/>, <https://onco.cc/cancers/cns-germ-cell-tumours/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:drugs <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:institutions <https://onco.cc/institutions/siop-europe/>, <https://onco.cc/institutions/dkfz/>, <https://onco.cc/institutions/st-jude/> ;
  onco:pathways <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/hedgehog/>, <https://onco.cc/pathways/myc/> ;
  onco:terms <https://onco.cc/terms/hereditary-cancer-syndromes/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-fruhwald-neuro-oncol/> ;
  onco:pipeline <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/trials/pediatric-match/> ;
  onco:standardOfCare <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/trials/acns0333/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/technologies/palliative-care/> .